Evidence map›Paper›PMID 21490144›Full record

ArticleThe American journal of clinical nutrition2011

Phenylbutyrate improves nitrogen disposal via an alternative pathway without eliciting an increase in protein breakdown and catabolism in control and ornithine transcarbamylase-deficient patients.

Juan C Marini, Brendan C Lanpher, Fernando Scaglia, William E O'Brien, Qin Sun, Peter J Garlick, Farook Jahoor, Brendan Lee

Abstract readControlled Clinical Trial
In one paragraph

Article in The American journal of clinical nutrition, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Juan C MariniUS Department of Agriculture/Agricultural Research Service Children's Nutrition Research Center, Departments of Pediatrics and Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Brendan C Lanpher
Fernando Scaglia
William E O'Brien
Qin Sun
Peter J Garlick
Farook Jahoor
Brendan Lee
Agricultural Research Service · US

Funding

Training (Career Development) ComponentU54HD061221 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI GROPMAN, ANDREA LYNNE · 2009 to 2023
$20.8M
Phenylbutyrate therapy for maple syrup urine diseaseR01DK092921 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI LEE, BRENDAN · 2011 to 2015
$3.3M
ENTERAL PRECURSORS FOR UREA SYNTHESIS IN HUMANSR01DK054450 · NIDDK · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI LEE, BRENDAN HL · 1998 to 2006
$1.6M
Mouse models for studying citrulline recycling for sustaining NO productionK01RR024173 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI MARINI, JUAN · 2007 to 2011
$614k
NCRR NIH HHS RR024173NICHD NIH HHS HD061221NICHD NIH HHS U54 HD061221NIDDK NIH HHS DK54450NIDDK NIH HHS R01 DK054450NIDDK NIH HHS R01 DK092921
6 · The paper itself

Abstract

backgroundPhenylbutyrate is a drug used in patients with urea cycle disorder to elicit alternative pathways for nitrogen disposal. However, phenylbutyrate administration decreases plasma branched-chain amino acid (BCAA) concentrations, and previous research suggests that phenylbutyrate administration may increase leucine oxidation, which would indicate increased protein degradation and net protein loss.

objectiveWe investigated the effects of phenylbutyrate administration on whole-body protein metabolism, glutamine, leucine, and urea kinetics in healthy and ornithine transcarbamylase-deficient (OTCD) subjects and the possible benefits of BCAA supplementation during phenylbutyrate therapy.

designSeven healthy control and 7 partial-OTCD subjects received either phenylbutyrate or no treatment in a crossover design. In addition, the partial-OTCD and 3 null-OTCD subjects received phenylbutyrate and phenylbutyrate plus BCAA supplementation. A multitracer protocol was used to determine the whole-body fluxes of urea and amino acids of interest.

resultsPhenylbutyrate administration reduced ureagenesis by ≈15% without affecting the fluxes of leucine, tyrosine, phenylalanine, or glutamine and the oxidation of leucine or phenylalanine. The transfer of (15)N from glutamine to urea was reduced by 35%. However, a reduction in plasma concentrations of BCAAs due to phenylbutyrate treatment was observed. BCAA supplementation did not alter the respective baseline fluxes.

conclusionsProlonged phenylbutyrate administration reduced ureagenesis and the transfer of (15)N from glutamine to urea without parallel reductions in glutamine flux and concentration. There were no changes in total-body protein breakdown and amino acid catabolism, which suggests that phenylbutyrate can be used to dispose of nitrogen effectively without adverse effects on body protein economy.

Indexed as

AdolescentAdultAgedAmino AcidsAmino Acids, Branched-ChainChildFemaleGlutamineHumansMaleMetabolic Networks and PathwaysMiddle AgedNitrogenOrnithine Carbamoyltransferase Deficiency DiseasePhenylbutyratesProteinsAmino AcidsAmino Acids, Branched-ChainGlutamineNitrogenPhenylbutyratesProteinsUrea

Identifiers

PMID21490144
PMCPMC3095500
OpenAlexW2168418336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.